Edition:
United Kingdom

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

9.78USD
13 Dec 2017
Change (% chg)

$0.21 (+2.19%)
Prev Close
$9.57
Open
$9.62
Day's High
$9.86
Day's Low
$9.62
Volume
16,615
Avg. Vol
21,272
52-wk High
$10.55
52-wk Low
$5.85

Latest Key Developments (Source: Significant Developments)

Recro Pharma secures $100 million credit facility
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Recro Pharma Inc :Recro Pharma Inc secures $100 million credit facility.Recro Pharma Inc - ‍has secured a $100 million credit facility from funds managed by Athyrium Capital Management, LP​.Recro Pharma Inc - ‍proceeds from facility to refinance Recro's outstanding debt, pay $45 million milestone to alkermes upon approval of iv meloxicam 30mg by FDA​.  Full Article

Recro Pharma reports Q3 revenue $17.1 million
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Recro Pharma Inc :Recro Pharma reports third quarter 2017 financial results.Q3 revenue $17.1 million versus I/B/E/S view $13.7 million.Recro Pharma Inc - ‍Raising its guidance for 2017 revenue from a range of $60-$63 million to $65 million​.Recro Pharma Inc qtrly ‍revenues were $17.1 million versus $17.0 million​.Recro Pharma Inc - ‍As of September 30, 2017, Recro had cash, cash equivalents and short-term investments of $41.3 million​.  Full Article

Recro Pharma says offering of 6.50 mln shares priced at $6/share
Tuesday, 13 Dec 2016 

Recro Pharma Inc: Recro Pharma announces pricing of public offering of common stock .Says public offering of 6.50 million common shares priced at $6.00 per share.  Full Article

Recro reports pricing of public offering of common stock
Tuesday, 16 Aug 2016 

Recro Pharma Inc : Recro Pharma announces pricing of public offering of common stock .Recro Pharma Inc says pricing of an underwritten public offering of 1,986,666 shares of its common stock at a price of $7.50 per share.  Full Article

Recro Pharma announces proposed public offering of common stock
Monday, 15 Aug 2016 

Recro Pharma Inc :Recro pharma announces proposed public offering of common stock.  Full Article

Recro Pharma Q2 loss per share $0.83
Thursday, 11 Aug 2016 

Recro Pharma Inc : Recro Pharma reports second quarter 2016 financial results . Q2 revenue $17.3 million versus $18.7 million .Sees FY 2016 revenue $55 million to $60 million.  Full Article

Recro Pharma appoints Michael Celano as CFO
Tuesday, 5 Jul 2016 

Recro Pharma Inc - :Recro Pharma appoints Michael Celano as chief financial officer.  Full Article

Recro Pharma Inc initiates pivotal phase iii clinical trial of IV Meloxicam for Acute Postoperative Pain
Wednesday, 27 Jan 2016 

Recro Pharma Inc:Announces that the first patient was dosed in the pivotal Phase III clinical trial evaluating intravenous (IV) meloxicam (N1539) for acute postoperative pain in patients following "mini" abdominoplasty surgery.Recro expects to report top-line results from this Phase III study by year end 2016.  Full Article

Recro Pharma, Inc says reports positive top-line results for phase II clinical trial of IV Meloxicam
Wednesday, 6 Jan 2016 

Recro Pharma, Inc:Says reports positive top-line results for phase II clinical trial of IV meloxicam.Says company on track to initiate pivotal phase III in 1q 2016.Says safety results demonstrated that IV meloxicam was well tolerated with no serious adverse events.Says both IV meloxicam treatment arms demonstrated statistically significant reductions in pain intensity.  Full Article

BRIEF-Recro Pharma secures $100 million credit facility

* Recro Pharma Inc - ‍has secured a $100 million credit facility from funds managed by Athyrium Capital Management, LP​